On this page of StockholderLetter.com we present the latest annual shareholder letter from REVVITY, INC. — ticker symbol RVTY. Reading current and past RVTY letters to shareholders can bring important insights into the investment thesis.
At the inflection point of scientific progress. 2025 Annual Report
We are helping 2
Dear Shareholders, As I look back on 2025, I am struck by the extraordinary moment we find ourselves in, one where science, technology, and human potential are converging in ways few could have imagined even a decade ago. At Revvity, we are embracing this inflection point with purpose and optimism, confident in our ability to help shape a future where disease is detected earlier, therapies are discovered faster, and health outcomes are improved for people everywhere. This year, artificial intelligence became an even more integral part of how we operate and how our customers innovate. AI is no longer an enhancement; it is a new foundation for scientific progress. We deployed next-generation AI tools across our global workforce, empowering teams to work more creatively and efficiently. And with solutions like the Signals Xynthetica platform, we are bringing the power of predictive science directly into the daily workflows of researchers. When these models are paired with real experimental data, the pace of discovery accelerates and the possibilities expand. Across our Diagnostics business, we are also harnessing AI to enhance accuracy in early disease detection, reduce time-to-diagnosis, and support more informed clinical decision-making. From reproductive health and newborn screening to infectious disease testing, AI-driven insights are helping providers identify risk earlier, intervene sooner, and ultimately improve patient outcomes. 2025 was also a year in which our company s leadership and innovation were on full display not just as a vendor, but as a strategic partner to our customers. Through our expanded partnership with Genomics England, we are helping advance the first large-scale newborn genome screening initiative of its kind. With Sanofi, we are enabling population-scale screening for Type 1 diabetes risk, an advancement that has the potential to change the trajectory of a lifelong disease. These efforts remind us that when innovation meets intention, science can transform lives in powerful ways. Across Revvity, our teams continued to push the boundaries of what s possible in other areas as well. We received FDA approval for a new automated solution for latent tuberculosis detection, supporting the global fight against one of the world s most persistent infectious diseases. We opened our In Vivo Imaging Center of Excellence, a place where the next generation of imaging technologies is already taking shape. And Revvity employees attend ribbon cutting at Genomics England (UK) lab. Revvity employees celebrate opening of the In Vivo Imaging Center of Excellence (NC, USA).
we further strengthened our portfolio and customer solutions through ongoing innovation, enabling us to deliver durable, highquality growth while advancing our purpose. Our vision also extends to the way we operate. In 2025, we made meaningful progress toward our sustainability goals by reducing emissions, surpassing our waste diversion target two years ahead of schedule, and earning an AAA ESG rating from investment research firm MSCI. We also recognize that people are the driving force behind scientific breakthroughs. That s why in 2025 we expanded the Revvity Access STEM Scholarships to help cultivate the next generation of scientific leaders and invested in initiatives to strengthen our workplace environment and employee experience. Reflecting this high-trust, employeefocused approach, Revvity was recognized globally as a Great Place to Work . Looking ahead, I am more inspired than ever by the work we do and the impact we can make. The distance between early discovery and clinical care is shrinking. The complexity of disease biology is giving rise to new opportunities for precision medicine. And AI is redefining the boundaries of speed, insight, and possibility. Revvity is built for this moment, powered by a transformed portfolio, guided by a clear purpose, and united by a belief that science can improve lives in ways we are only beginning to imagine. Thank you for your continued trust and partnership. Together, we are building not only a stronger company, but a brighter and healthier future for generations to come. Regards, Prahlad Revvity is built for this moment, powered by a transformed portfolio, guided by a clear purpose, and united by a belief that science can improve lives in ways we are only beginning to imagine. Prahlad Singh, PhD President and CEO D
Corporate Governance Board of Directors Corporate Officers Prahlad Singh, PhD President and Chief Executive Officer Revvity, Inc. Prahlad Singh, PhD President and Chief Executive Officer Peter Barrett, PhD Partner Atlas Venture Joel S. Goldberg Senior Vice President, Administration, General Counsel and Secretary Samuel R. Chapin Retired Executive Vice Chairman Bank of America Merrill Lynch Michael A. Klobuchar Chief Operating Officer Eikon Therapeutics, Inc. Michelle McMurry-Heath, MD, PhD Founder and Chief Executive Officer BioTechquity Clinical Max Krakowiak Senior Vice President and Chief Financial Officer Miriame Victor Senior Vice President, Chief Commercial Officer Alexis P. Michas Managing Partner Juniper Investment Company, LLC Tajinder Vohra Senior Vice President, Global Operations Sophie V. Vandebroek, PhD Former Vice President, Emerging Technology Partnerships IBM Corporation Anita Gonzales Vice President and Chief Accounting Officer Michel Vounatsos Former Chief Executive Officer Biogen Inc. Frank Witney, PhD Former Chief Executive Officer Affymetrix, Inc. Pascale Witz Founder and President PWH Advisors
 • shareholder letter icon 3/16/2026 Letter Continued (Full PDF)
 • stockholder letter icon 3/8/2023 RVTY Stockholder Letter
 • stockholder letter icon 3/13/2024 RVTY Stockholder Letter
 • stockholder letter icon 3/12/2025 RVTY Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon RVTY Benford's Law Stock Score = 80


RVTY Shareholder/Stockholder Letter Transcript:

At the inflection point
of scientific progress.
2025 Annual Report

We are helping


2

Dear Shareholders,
As I look back on 2025, I am struck by the extraordinary moment we find ourselves in, one where
science, technology, and human potential are converging in ways few could have imagined even a
decade ago. At Revvity, we are embracing this inflection point with purpose and optimism, confident in
our ability to help shape a future where disease is detected earlier, therapies are discovered faster, and
health outcomes are improved for people everywhere.
This year, artificial intelligence became an even more integral part of how we operate and how our
customers innovate. AI is no longer an enhancement; it is a new foundation for scientific progress. We
deployed next-generation AI tools across our global workforce, empowering teams to work more
creatively and efficiently. And with solutions like the Signals Xynthetica platform, we are bringing the
power of predictive science directly into the daily workflows of researchers. When these models are
paired with real experimental data, the pace of discovery accelerates and the possibilities expand.
Across our Diagnostics business, we are also harnessing AI to enhance accuracy in early disease
detection, reduce time-to-diagnosis, and support more informed clinical decision-making. From
reproductive health and newborn screening to infectious
disease testing, AI-driven insights are helping providers
identify risk earlier, intervene sooner, and ultimately
improve patient outcomes.
2025 was also a year in which our company   s leadership
and innovation were on full display     not just as a vendor,
but as a strategic partner to our customers. Through
our expanded partnership with Genomics England,
we are helping advance the first large-scale newborn
genome screening initiative of its kind. With Sanofi, we are
enabling population-scale screening for Type 1 diabetes
risk, an advancement that has the potential to change the
trajectory of a lifelong disease.
These efforts remind us that when innovation
meets intention, science can transform lives
in powerful ways. Across Revvity, our teams
continued to push the boundaries of what   s
possible in other areas as well. We received
FDA approval for a new automated solution
for latent tuberculosis detection, supporting
the global fight against one of the world   s most
persistent infectious diseases. We opened
our In Vivo Imaging Center of Excellence, a
place where the next generation of imaging
technologies is already taking shape. And
Revvity employees attend ribbon cutting at
Genomics England (UK) lab.
Revvity employees celebrate opening of the In Vivo Imaging Center
of Excellence (NC, USA).

we further strengthened our portfolio and customer solutions
through ongoing innovation, enabling us to deliver durable, highquality growth while advancing our purpose.
Our vision also extends to the way we operate. In 2025, we
made meaningful progress toward our sustainability goals by
reducing emissions, surpassing our waste diversion target two
years ahead of schedule, and earning an AAA ESG rating from
investment research firm MSCI. We also recognize that people
are the driving force behind scientific breakthroughs. That   s why
in 2025 we expanded the Revvity Access STEM Scholarships
to help cultivate the next generation of scientific leaders and
invested in initiatives to strengthen our workplace environment
and employee experience. Reflecting this high-trust, employeefocused approach, Revvity was recognized globally as a Great
Place to Work  .
Looking ahead, I am more inspired than ever by the work we
do and the impact we can make. The distance between early
discovery and clinical care is shrinking. The complexity of
disease biology is giving rise to new opportunities for precision
medicine. And AI is redefining the boundaries of speed, insight,
and possibility. Revvity is built for this moment, powered by a
transformed portfolio, guided by a clear purpose, and united
by a belief that science can improve lives in ways we are only
beginning to imagine.
Thank you for your continued trust and partnership. Together,
we are building not only a stronger company, but a brighter and
healthier future for generations to come.
Regards,
Prahlad
   Revvity is built for this
moment, powered by a
transformed portfolio, guided
by a clear purpose, and united
by a belief that science can
improve lives in ways we are
only beginning to imagine.   
Prahlad Singh, PhD
President and CEO
                  D      

Corporate Governance
Board of Directors
Corporate Officers
Prahlad Singh, PhD
President and Chief Executive Officer
Revvity, Inc.
Prahlad Singh, PhD
President and Chief Executive Officer
Peter Barrett, PhD
Partner
Atlas Venture
Joel S. Goldberg
Senior Vice President,
Administration, General
Counsel and Secretary
Samuel R. Chapin
Retired Executive Vice Chairman
Bank of America Merrill Lynch
Michael A. Klobuchar
Chief Operating Officer
Eikon Therapeutics, Inc.
Michelle McMurry-Heath, MD, PhD
Founder and Chief Executive Officer
BioTechquity Clinical
Max Krakowiak
Senior Vice President and
Chief Financial Officer
Miriame Victor
Senior Vice President,
Chief Commercial Officer
Alexis P. Michas
Managing Partner
Juniper Investment Company, LLC
Tajinder Vohra
Senior Vice President, Global Operations
Sophie V. Vandebroek, PhD
Former Vice President,
Emerging Technology Partnerships
IBM Corporation
Anita Gonzales
Vice President and Chief Accounting Officer
Michel Vounatsos
Former Chief Executive Officer
Biogen Inc.
Frank Witney, PhD
Former Chief Executive Officer
Affymetrix, Inc.
Pascale Witz
Founder and President
PWH Advisors


shareholder letter icon 3/16/2026 Letter Continued (Full PDF)
 

RVTY Stockholder/Shareholder Letter (REVVITY, INC.) | www.StockholderLetter.com
Copyright © 2023 - 2026, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.